Figure 4.

FGF2 secreted from endothelial cells induces ETS related gene (ERG) expression and docetaxel resistance in prostate cancer cells. (A) The cytokines array analysis. The conditioned media collected from 22Rv1, 22Rv1, and human umbilical vein endothelial cells (HUVEC) co-culture systems were used for the analysis. (B) Histogram showing increased cytokines in 22Rv1 and HUVEC co-culture supernatant compared to 22Rv1 culture supernatant. (C) Western blot analysis of ERG expression following FGF2 treatment in prostate cancer cells. 22Rv1 and C4–2B cells (1×10⁵/well) were treated with 20 ng/ml and 50 ng/ml of FGF2 for 48 h, respectively. (D) Quantitative PCR analysis of FGF2 expression in HUVEC cultured with or without prostate cancer cells. (E) ELISA demonstrating different FGF2 concentrations in culture supernatants from HUVEC and HUVEC co-cultured with prostate cancer cells. (F, G) 22Rv1 and C4-2B cells were cultured with or without HUVEC in the presence or absence of anti-FGF2 for 48h. (F) Western blot analysis of ERG expression of prostate cancer cells was conducted. (G) Cell viability assay of prostate cancer cells treated with 10 nM docetaxel for 48 h was performed. Data were presented as mean ± SD; *P < 0.05; **P < 0.01.